Table S4. Expanded List of Treatment Emergent Adverse Events of Importance Type of Adverse Event, n(%) RPV/FTC/TDF EFV/FTC/TDF P value n = 394 n = 392 Nervous system events 117 (29.7%) 198 (50.5%) <.001 Amnesia 6 (1.5%) 1 (0.3%) Balance disorder 0 3 (0.8%) Convulsion 0 2 (0.5%) Disturbance in attention 6 (1.5%) 11 (2.8%) Dizziness 26 (6.6%) 87 (22.2%) Headache 49 (12.4%) 53 (13.5%) Hypoaesthesia 6 (1.5%) 4 (1.0%) Insomnia 38 (9.6%) 55 (14.0%) Neuropathy peripheral 1 (0.3%) 6 (1.5%) Parasthesia 9 (2.3%) 16 (4.1%) Somnolence 10 (2.5%) 27 (6.9%) Stupor 0 2 (0.5%) Tremor 1 (0.3%) 3 (0.8%) Vertigo 4 (1.0%) 10 (2.6%) Psychiatric events 62 (15.7%) 147 (37.5%) <.001 Abnormal dreams 23 (5.8%) 96 (24.5%) Affect lability 0 1 (0.3%) Aggression 1 (0.3%) 0
Table S4. Expanded List of Treatment Emergent Adverse Events of Importance Type of Adverse Event, n(%) RPV/FTC/TDF n = 394 EFV/FTC/TDF n = 392 P value Nervous system events 117 (29.7%) 198 (50.5%) <.001 Amnesia Balance disorder Convulsion Disturbance in attention Dizziness 6 (1.5%) 0 0 6 (1.5%) 26 (6.6%) 1 (0.3%) 3 (0.8%) 2 (0.5%) 11 (2.8%) 87 (22.2%) Headache 49 (12.4%) 53 (13.5%) Hypoaesthesia Insomnia Neuropathy peripheral Parasthesia Somnolence Stupor Tremor Vertigo 6 (1.5%) 38 (9.6%) 1 (0.3%) 9 (2.3%) 10 (2.5%) 0 1 (0.3%) 4 (1.0%) 4 (1.0%) 55 (14.0%) 6 (1.5%) 16 (4.1%) 27 (6.9%) 2 (0.5%) 3 (0.8%) 10 (2.6%) Psychiatric events 62 (15.7%) 147 (37.5%) <.001 Abnormal dreams Affect lability Aggression 23 (5.8%) 0 1 (0.3%) 96 (24.5%) 1 (0.3%) 0
QAD_2014_01_04_COHEN_AIDS-D-13-00893_SDC1.docx